These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering. Lose JM; Dorsch MP; Bleske BE Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812 [TBL] [Abstract][Full Text] [Related]
24. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719 [TBL] [Abstract][Full Text] [Related]
25. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia. Jelassi A; Slimani A; Jguirim I; Najah M; Maatouk F; Varret M; Slimane MN Ann Clin Biochem; 2011 Jan; 48(Pt 1):83-6. PubMed ID: 21115573 [TBL] [Abstract][Full Text] [Related]
26. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype. Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983 [TBL] [Abstract][Full Text] [Related]
27. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916 [TBL] [Abstract][Full Text] [Related]
28. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels. Huijgen R; Sjouke B; Vis K; de Randamie JS; Defesche JC; Kastelein JJ; Hovingh GK; Fouchier SW Hum Mutat; 2012 Feb; 33(2):448-55. PubMed ID: 22095935 [TBL] [Abstract][Full Text] [Related]
29. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937 [TBL] [Abstract][Full Text] [Related]
30. Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes. Baila-Rueda L; Pérez-Ruiz MR; Jarauta E; Tejedor MT; Mateo-Gallego R; Lamiquiz-Moneo I; de Castro-Orós I; Cenarro A; Civeira F Atherosclerosis; 2016 Mar; 246():202-7. PubMed ID: 26802983 [TBL] [Abstract][Full Text] [Related]
31. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Hooper AJ; Marais AD; Tanyanyiwa DM; Burnett JR Atherosclerosis; 2007 Aug; 193(2):445-8. PubMed ID: 16989838 [TBL] [Abstract][Full Text] [Related]
32. The study of familial hypercholesterolemia in Italy: A narrative review. Bertolini S; Pisciotta L; Fasano T; Rabacchi C; Calandra S Atheroscler Suppl; 2017 Oct; 29():1-10. PubMed ID: 28965614 [TBL] [Abstract][Full Text] [Related]
33. Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations. Martin R; Latten M; Hart P; Murray H; Bailie DA; Crockard M; Lamont J; Fitzgerald P; Graham CA Atherosclerosis; 2016 Nov; 254():8-13. PubMed ID: 27680772 [TBL] [Abstract][Full Text] [Related]
34. PCSK9: a key modulator of cardiovascular health. Seidah NG; Awan Z; Chrétien M; Mbikay M Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727 [TBL] [Abstract][Full Text] [Related]
35. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes. Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273 [TBL] [Abstract][Full Text] [Related]
36. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251 [TBL] [Abstract][Full Text] [Related]